[18F]Fluorodeoxyglucose-PET/CT differentiation between physiological and pathological accumulations in head and neck

Nuclear Medicine Communications

Volumn 30, Issue 7, 2009, Pages 498-503

  Nakamura, Shin ^a   Okochi, Kiyoshi ^a   Murata, Yuji ^b   Shibuya, Hitoshi ^a   Kurabayashi, Tohru ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Kojin Hospital   (Japan)

Author keywords

Fluorine 18 labeled fluorodeoxyglucose; Head and neck; Physiological fluorodeoxyglucose accumulation; Positron emission tomography computed tomography

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CALCULATION; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; EXTRAOCULAR MUSCLE; FEMALE; HEAD; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; INJECTION; MAJOR CLINICAL STUDY; MALE; MASTICATORY MUSCLE; NECK; PAROTID GLAND; PATHOLOGY; PHYSIOLOGY; SUBLINGUAL GLAND; SUBMANDIBULAR GLAND; TONSIL; VOCAL CORD; COMPUTER ASSISTED TOMOGRAPHY; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; RETROSPECTIVE STUDY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NECK; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 67650330195     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283299a52     Document Type: Article

References (21)

1. Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose(F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21:670-675.
2. Lauenbacher C, Saumweber D, Wagner-Manslau C, Kau RJ, Herz M, Avril N, et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI, and endoscopy for staging head and neck squamous-cell carcinoma. J Nucl Med 1995; 36:1747-1757.
3. Braams JW, Pruim J, Freling NJM, Nikkels PGJ, Roodenburg JLN, Boering G, et al. Detection of lymph nodes metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 1995; 36:211-216.
4. Ng SH, Yen TC, Chang JTC, Chan SC, Ko SF, Wang HM, et al. Prospective study of [18F] fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol 2006; 24:4371-4376.
5. Li P, Zhuang H, Mozley PD, Denittis A, Yeh D, Machtay M, et al. Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography. Clin Nucl Med 2001; 26:131-135.
6. Rusthoven KE, Kosly M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary. Cancer 2004; 101:2641-2649.
7. Schoder H, Yeung HWD, Gonen M, Kraus D, Larson SM. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004; 231:65-72.
8. Engel H, Steinert H, Buck A, Berthold T, Huch Boni RA, von Schulthess GK. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 1996; 37:441-446.
9. 18F]fluoro-2- deoxy-D-glucose. J comput Assist Tomogr 1993; 17:582-589.
10. Murata Y, Watanabe H, Kubota K, Toda K, Nakamura S, Okouchi K, et al. PET/CT evaluation of the physiologic accumulation of 18F-FDG within the gallbladder vesicle. Nucl Med Biol 2007; 34:961-966.
11. Kostankoglu L, Wong J, Barrington SF, Cronin BF, Dynes AM, Maisey MN. Speech-related visualization of laryngeal muscles with fluorine-18-FDG. J Nucl Med 1996; 37:1771-1773.
12. Kawabe J, Okamura T, Shakudo M, Koyama K, Sakamoto H, Ohachi Y, et al. Physiological FDG uptake in the palatine tonsils. Ann Nucl Med 2001; 15:297-300.
13. Wong WL, Gibson D, Sanghera B, Goodchild K, Saunders M. Evaluation of normal FDG uptake in palatine tonsil and its potential value for detecting occult head and neck cancers: A PET CT study. Nucl Med commun 2007; 28:675-680.
14. Nakamoto Y, Tatsumi M, Hammoud D, Cohade C, Osman MM, Wahl RL. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology 2005; 234:879-885.
15. Uematsu H, Sadato N, Yonekura Y, Tsuchida T, Nakamura S, Sugimoto K, et al. Coregistration of FDG PET and MRI of the head and neck using normal distribution of FDG. J Nucl Med 1998; 39:2121-2127.
16. Jabour BA, Choi Y, Hoh CK, Rege SD, Soong JC, Lufkin RB, et al. Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology 1993; 186:27-35.
17. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007; 48:932-945.
18. Teo BK, Seo Y, Bacharach SL, Carrasquillo JA, Libutti SK, Shukla H, et al. Partial-volume correction in PET: validation of an iterative postreconstruction method with phantom and patient data. J Nucl Med 2007; 48:802-810.
19. Goerres GW, Hany TF, Kamel E, von Schulthess GK, Buck A. Head and neck imaging with PET and PET/CT: artifacts from dental metallic implants. Eur J Nucl Med Mol Imaging 2002; 29:367-370.
20. Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999; 26:1345-1348.
21. Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 2001; 28:696-703.